section name header

Information

[Section Outline]

Urethritis In MEN !!navigator!!

Microbiology and Epidemiology !!navigator!!

Most cases are caused by either Neisseria gonorrhoeae or Chlamydia trachomatis. Other causative organisms include Mycoplasma genitalium, Ureaplasma urealyticum, Trichomonas vaginalis, HSV, and occasionally anaerobes (especially Leptotrichia/Sneathia species) involved in bacterial vaginitis. Chlamydia causes 30-40% of nongonococcal urethritis (NGU) cases. M. genitalium is the probable cause in many Chlamydia-negative cases of NGU.

Clinical Manifestations !!navigator!!

Urethritis in men produces urethral discharge, dysuria, or both, usually without frequency of urination.

Diagnosis !!navigator!!

Pts present with a mucopurulent urethral discharge that can usually be expressed by milking of the urethra; alternatively, a Gram's-stained smear of an anterior urethral specimen containing 2 PMNs/1000× field confirms the diagnosis.

  • Centrifuged sediment of the day's first 20-30 mL of voided urine can be examined for inflammatory cells instead.
  • N. gonorrhoeae can be presumptively identified if intracellular gram-negative diplococci are present in Gram's-stained samples.
  • Early-morning, first-voided urine should be used in “multiplex” nucleic acid amplification tests (NAATs) for N. gonorrhoeae and C. trachomatis.
TREATMENT

Urethritis in Men

  • Treatment should be given promptly, while test results are pending.
    • Unless these diseases have been excluded, gonorrhea is treated with a single dose of ceftriaxone (250 mg IM) plus azithromycin (1 g PO once), and Chlamydia infection is treated with azithromycin (1 g PO once) or doxycycline (100 mg bid for 7 days); the efficacy of azithromycin for treatment of M. genitalium is rapidly declining.
    • Sexual partners of the index case should receive the same treatment.
  • For recurrent symptoms: With re-exposure, both pt and partner are re-treated. Without re-exposure, infection with T. vaginalis (with culture or NAATs of a urethral swab and early-morning, first-voided urine) or antibiotic-resistant M. genitalium or Ureaplasma should be considered; treatment with metronidazole, azithromycin (1 g PO once), or both is recommended, and the azithromycin component is especially important if this drug was not used for the primary episode. Moxifloxacin can be considered for treatment of refractory nongonococcal, nonchlamydial urethritis.

Epididymitis !!navigator!!

Microbiology

In sexually active men <35 years old, epididymitis is caused most frequently by C. trachomatis and less commonly by N. gonorrhoeae.

  • In older men or after urinary tract instrumentation, urinary pathogens are most common.
  • In men who practice insertive rectal intercourse, Enterobacteriaceae may be responsible.

Clinical Manifestations

Acute epididymitis-almost always unilateral-produces pain, swelling, and tenderness of the epididymis, with or without symptoms or signs of urethritis. Epididymitis must be differentiated from testicular torsion, tumor, and trauma. If symptoms persist after treatment, a testicular tumor or a chronic granulomatous disease (e.g., tuberculosis) should be considered.

TREATMENT

Epididymitis

  • Ceftriaxone (250 mg IM once) followed by doxycycline (100 mg PO bid for 10 days) is effective for epididymitis due to C. trachomatis or N. gonorrhoeae.
  • Oral cephalosporins and fluoroquinolones are no longer recommended because of increasing resistance in N. gonorrhoeae.
  • If Enterobacteriaceae are suspected as the cause and such organisms are detected in a urine culture, levofloxacin (500 mg PO daily for 10 days) or ofloxacin (300 mg PO bid for 10 days) can be used.

Urethritis (the Urethral Syndrome) In Women !!navigator!!

Microbiology and Clinical Manifestations

C. trachomatis, N. gonorrhoeae, and occasionally HSV cause symptomatic urethritis-known as the urethral syndrome in women-that is characterized by “internal” dysuria (usually without urinary urgency or frequency), pyuria, and an absence of Escherichia coli and other uropathogens at counts 102 /mL in urine.

Diagnosis

Specific tests (e.g., NAATs of vaginal secretions collected with a swab) are used to evaluate for infection with N. gonorrhoeae or C. trachomatis.

TREATMENT

Urethritis (The Urethral Syndrome) in Women

See “Urethritis in Men Sexually Transmitted and Reproductive Tract Infections,” above.

Vulvovaginal Infections !!navigator!!

Microbiology !!navigator!!

A variety of organisms are associated with vulvovaginal infections, including N. gonorrhoeae and C. trachomatis (particularly when they cause cervicitis), T. vaginalis, Candida albicans, Gardnerella vaginalis, and HSV.

Clinical Manifestations !!navigator!!

Vulvovaginal infections encompass a wide array of specific conditions, each of which has different presenting symptoms.

  • Unsolicited reporting of abnormal vaginal discharge suggests trichomoniasis or bacterial vaginosis (BV).
    • Trichomoniasis is characterized by vulvar irritation and a profuse white or yellow homogeneous vaginal discharge with a pH that is typically 5.
    • - BV is characterized by vaginal malodor and a slight to moderate increase in white or gray homogeneous vaginal discharge that uniformly coats the vaginal walls and typically has a pH >4.5.
    • Vaginal trichomoniasis and BV early in pregnancy are associated with premature onset of labor.
  • Vulvar conditions such as genital herpes or vulvovaginal candidiasis can cause vulvar pruritus, burning, irritation, or lesions as well as external dysuria (as urine passes over the inflamed vulva or areas of epithelial disruption) or vulvar dyspareunia.

Diagnosis !!navigator!!

Evaluation of vulvovaginal symptoms includes a pelvic examination (with a speculum examination) and diagnostic testing.

  • Abnormal vaginal discharge is assessed for pH, a fishy odor after mixing with 10% KOH (BV), evidence on microscopy of motile trichomonads and/or clue cells of BV (vaginal epithelial cells coated with coccobacillary organisms) when the specimen is mixed with saline, or hyphae or pseudohyphae on microscopy when 10% KOH is added (vaginal candidiasis).
  • A NAAT for T. vaginalis is available.
TREATMENT

Vulvovaginal Infections

  • Vulvovaginal candidiasis:Miconazole (a single 100-mg vaginal suppository), clotrimazole (100-mg vaginal tablets daily for 3-7 days), or fluconazole (150 mg PO once) are all effective.
  • Trichomoniasis: Metronidazole (2 g PO once or 500 mg PO bid for 7 days) is effective. Treatment of sexual partners with the same regimen reduces the risk of reinfection and is the standard of care.
  • BV: Metronidazole (500 mg PO bid for 7 days), 2% clindamycin cream (one full applicator vaginally each night for 7 days), or 0.75% metronidazole gel (one full applicator vaginally daily for 5 days) is effective, but recurrence is common regardless of the regimen used.

Mucopurulent Cervicitis !!navigator!!

Microbiology !!navigator!!

N. gonorrhoeae, C. trachomatis, and M. genitalium are the primary causes of mucopurulent cervicitis. Of note, NAATs for these pathogens, HSV, and T. vaginalis have been negative in nearly half of cases.

Clinical Manifestations !!navigator!!

Mucopurulent cervicitis represents the “silent partner” of urethritis in men and results from inflammation of the columnar epithelium and subepithelium of the endocervix.

Diagnosis !!navigator!!

Yellow mucopurulent discharge from the cervical os, with 20 PMNs/1000× field on Gram's stain of cervical mucus, indicates endocervicitis. The presence of intracellular gram-negative diplococci on Gram's stain of cervical mucus is specific but <50% sensitive for gonorrhea; thus NAATs for N. gonorrhoeae and C. trachomatis are always indicated.

TREATMENT

Pelvic Inflammatory Disease (Pid) !!navigator!!

Microbiology !!navigator!!

The agents most often implicated in acute PID-infection that ascends from the cervix or vagina to the endometrium and/or fallopian tubes-include the primary causes of endocervicitis (e.g., N. gonorrhoeae, C. trachomatis, M. genitalium) and anaerobes associated with BV; other organisms (e.g., Prevotella spp., peptostreptococci, E. coli, Haemophilus influenzae, and group B streptococci) account for 25-33% of cases.

Epidemiology !!navigator!!

In 2014, there were 51,000 visits to physicians' offices for PID in the United States; there are 70,000-100,000 hospitalizations related to PID annually.

  • Risk factors for PID include cervicitis, BV, a history of salpingitis or recent vaginal douching, menstruation, and recent insertion of an intrauterine contraceptive device (IUD).
  • Oral contraceptive pills decrease risk.

Clinical Manifestations !!navigator!!

The presenting symptoms depend on the extent to which the infection has spread.

  • Endometritis: Pts present with midline abdominal pain and abnormal vaginal bleeding. Lower-quadrant, adnexal, or cervical motion or abdominal rebound tenderness is less severe in women with endometritis alone than in women who also have salpingitis.
  • Salpingitis: Symptoms evolve from mucopurulent cervicitis to endometritis and then to bilateral lower abdominal and pelvic pain caused by salpingitis. Nausea, vomiting, and increased abdominal tenderness may occur if peritonitis develops.
  • Perihepatitis (Fitz-Hugh-Curtis syndrome): 3-10% of women present with pleuritic upper abdominal pain and tenderness in the RUQ due to perihepatic inflammation. Most cases are due to chlamydial salpingitis.
  • Periappendicitis:5% of pts can have appendiceal serositis without involvement of the intestinal mucosa as a result of gonococcal or chlamydial salpingitis.

Diagnosis !!navigator!!

Speculum examination shows evidence of mucopurulent cervicitis in the majority of pts with gonococcal or chlamydial PID; cervical motion tenderness, uterine fundal tenderness, and/or abnormal adnexal tenderness also is usually present. Vaginal or endocervical swab specimens should be obtained for NAATs for N. gonorrhoeae and C. trachomatis.

TREATMENT

Pelvic Inflammatory Disease

  • Empirical treatment for PID should be initiated in sexually active young women and in other women who are at risk for PID and who have pelvic or lower abdominal pain with no other explanation as well as cervical motion, uterine, or adnexal tenderness.
  • Hospitalization should be considered when (1) the diagnosis is uncertain and surgical emergencies cannot be excluded, (2) the pt is pregnant, (3) pelvic abscess is suspected, (4) severe illness precludes outpatient management, (5) the pt has HIV infection, (6) the pt is unable to follow or tolerate an outpatient regimen, or (7) the pt has failed to respond to outpatient therapy.
  • Outpatient regimen: Ceftriaxone (250 mg IM once) plus doxycycline (100 mg PO bid for 14 days) plus metronidazole (500 mg PO bid for 14 days) is effective. Women treated as outpatients should be clinically reevaluated within 72 h.
  • Parenteral regimens: Parenteral treatment with the two regimens listed below should be continued for 48 h after clinical improvement. A 14-day course should be completed with doxycycline (100 mg PO bid); if the clindamycin-containing regimen is used, this drug can be given by the oral route (450 mg PO qid).
    • Cefotetan (2 g IV q12h) or cefoxitin (2 g IV q6h) plus doxycycline (100 mg IV/PO q12h)
    • Clindamycin (900 mg IV q8h) plus gentamicin (loading dose of 2.0 mg/kg IV/IM followed by 1.5 mg/kg q8h)
  • Male sex partners should be evaluated and treated empirically for gonorrhea and chlamydial infection.

Prognosis

Late sequelae include infertility (11% after one episode of PID, 23% after two, and 54% after three or more); ectopic pregnancy (sevenfold increase in risk); chronic pelvic pain; and recurrent salpingitis.

Ulcerative Genital Lesions !!navigator!!

The most common etiologies for ulcerative genital lesions in the United States are genital herpes, syphilis, and chancroid. See Table 86-1 Clinical Features of Genital Ulcers and the sections on individual pathogens below for specific clinical manifestations. Pts with persistent genital ulcers that do not resolve with syndrome-based antimicrobial therapy should have their HIV serologic status assessed if such testing has not previously been performed. Immediate treatment (before all test results are available) is often appropriate to improve response, reduce transmission, and cover pts who might not return for follow-up visits.

Proctitis, Proctocolitis, Enterocolitis, and Enteritis !!navigator!!

Microbiology and Epidemiology !!navigator!!

Acquisition of HSV, N. gonorrhoeae, or C. trachomatis (including lymphogranuloma venereum [LGV] strains of C. trachomatis) during receptive anorectal intercourse causes most cases of infectious proctitis in women and in men who have sex with men (MSM). Sexually acquired proctocolitis is most often due to Campylobacter or Shigella spp. In MSM without HIV infection, enteritis is often attributable to Giardia lamblia.

Clinical Manifestations !!navigator!!

Anorectal pain and mucopurulent, bloody rectal discharge suggest proctitis or proctocolitis. Proctitis is more likely to cause tenesmus and constipation, whereas proctocolitis and enteritis more often cause diarrhea.

  • HSV proctitis and LGV proctocolitis can cause severe pain, fever, and systemic manifestations.
  • Sacral nerve root radiculopathy, with urinary retention or anal sphincter dysfunction, is associated with primary HSV infection.

Diagnosis !!navigator!!

Pts should undergo anoscopy to examine the rectal mucosa and exudates and to obtain specimens for testing for rectal gonorrhea, chlamydial infection, herpes, and syphilis.

TREATMENT

Proctitis, Proctocolitis, Enterocolitis, Enteritis

  • Pending test results, pts should receive empirical treatment for gonorrhea and chlamydial infection with ceftriaxone (250 mg IM once) followed by doxycycline (100 mg bid for 7 days); therapy for syphilis or herpes should be given as indicated.
  • If LGV proctitis is proven or suspected, doxycycline (100 mg PO bid for 21 days) should be given.

Outline

Section 7. Infectious Diseases